Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Callidus Biopharma Inc.

Division of Amicus Therapeutics Inc.

Latest From Callidus Biopharma Inc.

WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO

WuXi AppTec is planning to spin out its biologics CRO/CMO unit in a Hong Kong IPO that is likely to raise at least $367m, sources have confirmed. The new funding would provide the fast-growing Wuxi Biologics subsidiary with the freedom and resources to make its own pipeline portfolio decisions.

BioPharmaceutical Asia Pacific

Persistence Pays Off For Amicus: Positive Migalastat Data In Hand

Amicus will return to FDA with positive data on its oral small molecule chaperone migalastat in Fabry patients after a Phase III trial showed the oral drug had comparable efficacy to existing enzyme replacement therapies.

BioPharmaceutical Clinical Trials

Evolution Of A Chinese CRO: WuXi Explores New Growth Models

While investors are disappointed about the company’s Q1 outlook, WuXi is exploring more risk-sharing partnerships and a business model inspired by China e-commerce giant Alibaba.

BioPharmaceutical China

Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies

Amicus’ most promising candidate would improve upon Sanofi/Genzyme’s Pompe disease drug Lumizyme, but closer to the clinic is a program to combine Fabry disease candidate migalastat with an enzyme replacement therapy obtained in last year’s buyout of Callidus.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amicus Therapeutics Inc.
  • Senior Management
  • Paul Antony, MD, Pres. & CEO
  • Contact Info
  • Callidus Biopharma Inc.
    3805 Old Easton Rd.
    Doylestown, PA 18902